Bluesight vs Imprivata Patient Privacy Intelligence (2026)
Two approaches to finding a privacy violation that disagree at the root. Imprivata explains: it tries first to tie each access to a legitimate clinical reason, such as an appointment, an encounter or a diagnosis code, and flags only what it cannot account for. That is a claim about the evidence rather than about the person. Bluesight's PrivacyPro, the former Protenus platform, scores each access with machine learning and groups suspicious ones into cases, and Bluesight also sells diversion monitoring through ControlCheck. Imprivata's method has peer reviewed research behind it, though much of it predates the FairWarning and Maize merger, so confirm which capabilities carried over. If keeping false accusations down is the priority, start with Imprivata. If privacy and diversion monitoring from one vendor matters more, start with Bluesight.
- Privacy monitoring and diversion monitoring come from one vendor, through PrivacyPro and ControlCheck.
- PrivacyPro scores every staff access to patient records with machine learning and groups related incidents into cases, instead of sampling a fraction of accesses.
- PrivacyPro covers hospitals, health systems and physician groups.
- It explains each access against a legitimate clinical reason and surfaces only the residue it cannot account for, so it does not flag people for being unusual.
- The Explanation Based Auditing research behind it reported explanations for over 94 percent of accesses against a real health system log, and the work has been cited more than 50 times.
- The system runs in a virtual machine inside the customer environment, and the vendor tells customers to keep manual review running until they have validated it themselves.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Bluesight and Imprivata Patient Privacy Intelligence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Bluesight | Imprivata Patient Privacy Intelligence |
|---|---|---|
| Primary category | Healthcare Cybersecurity | Healthcare Cybersecurity |
| Founded | 2011 | Not recorded |
| Headquarters | Alexandria, Virginia, United States | Waltham, Massachusetts, United States |
| Website | bluesight.com | imprivata.com |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Healthcare Cybersecurity page.
Both are consequential workforce surveillance tools. The methods differ at the root: Imprivata matches accesses against legitimate reasons and flags the unexplained residue, while PrivacyPro scores behavior. Bluesight publishes no fairness evaluation or false accusation rate, and its stated 95 percent accuracy comes without a method or denominator.
Imprivata's peer reviewed record and its in customer deployment model largely predate the merger into Patient Privacy Intelligence, so ask which carried over. Bluesight's 2022 SOC 2 Type 2 announcement predates the Protenus acquisition. Neither publishes a price.